Previously untreated, CD20-positive follicular lymphoma
Conditions
Interventions
Intravenous or subcutaneous rituximab
CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone)
Sponsors
Okugaito Izumi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Japanese patients with follicular lymphoma grade 1, 2, or 3a , according to the WHO classification system (2017) 2. No prior follwing treatment for non-Hodgkin lymphoma : chemotherapy, antibody therapy, immunosuppressive chemotherapy, radioimmunotherapy, hematopoietic stem-cell transplantation 3. Patients with at least one of GELF criteria 4. ECOG performance status of 0-2 5. Age 20 years or more, but age 80 years or younger at the time of informed consent 6. Life expectancy of 6 months or more 7. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Histologically proven transformation after the diagnosis of follicular lymphoma grade 1, 2 or 3a 2. Patients with HIV antibody. Patients with active hepatitis infection. One or more positive test results for HBs antigen, HBs antibody, HBc antibody or HCV antibody. 3. Patients with diabete treating with insulin 4. Patients with active multiple cancer 5. Patients with severe heart disease or lung disease 6. CNS involvement of lymphoma 7. Patients with severe psychological conditions 8. Pregnancy or nursing females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate(ORR) at the completion of induction therapy | — |
Contacts
Public ContactIzumi Okugaito
Zenyaku Kogyo Co.,Ltd
Outcome results
None listed